US jury says Apple must pay Masimo $634 million in smartwatch patent case

A federal jury has ordered Apple to pay Masimo $634 million for infringing a patent related to blood-oxygen reading technology in the Apple Watch, specifically concerning its workout mode and heart rate notification features. Apple has stated it disagrees with the verdict and will appeal. This ruling is a significant development in the contentious, multi-front intellectual property dispute between the companies, which previously led to a U.S. trade tribunal import ban on certain Apple Watch models and continues to involve legal challenges regarding updated devices.

Analysis

A federal jury has ordered Apple (AAPL) to pay Masimo (MASI) $634 million for infringing a patent related to blood-oxygen reading technology in the Apple Watch, specifically concerning its workout mode and heart rate notification features. Apple has immediately stated its disagreement with the verdict and confirmed its intention to appeal, indicating the judgment is not final. Masimo, conversely, views this as a "significant win" in protecting its intellectual property. This outcome contributes to a strongly negative sentiment for AAPL (-0.8) and strongly positive for MASI (0.8).

Key Decisions for Investors

• Investors should closely monitor Apple's appeal process, as the $634 million judgment is not final and could be significantly altered, impacting the ultimate financial liability.
• Evaluate the potential for ongoing operational and supply chain disruptions for Apple, given the continued ITC proceedings and Masimo's lawsuit against U.S. Customs regarding updated Apple Watch models.
• Assess the broader implications of this intellectual property dispute on Apple's future innovation roadmap and Masimo's enhanced position in monetizing its patent portfolio within the health technology sector.